Residual glucocorticoid use at Boolean remission in rheumatoid arthritis: An analysis of the Fukuoka Rheumatoid Arthritis Network (FRANK) Registry
Authors' conclusion
Residual GC use at remission did not improve remission maintenance.
Study context
- Population
- Patients with rheumatoid arthritis (RA) who newly achieved Boolean remission between 2018 and 2023, FRANK registry
- Participants
- 411 patients
- Exposure
- Residual oral GC use vs no GC use at Boolean remission
- GC usersn = 130
- GC non-usersn = 281reference
- Outcome
- Time to loss of Boolean remission
Methodological detailsmulticentre prospective registry, propensity score-based inverse probability of treatment weighting (IPTW)
- Multicentre prospective registry
- Propensity score-based IPTW
Main finding
As reported in the abstract
- No significant difference in time to loss of remission
- IPTW-adjusted
Observational data: associations, not effects.
Secondary outcomes
Longitudinal Clinical Disease Activity Index (CDAI), modified Health Assessment Questionnaire (mHAQ) and EQ-5D scores
- Trajectories comparable between groups
Safety
Herpes zoster, acute coronary syndrome and stroke
- Safety events numerically higher in GC users
- Very low number of events precludes definitive conclusions
Original publication
Residual glucocorticoid use at Boolean remission in rheumatoid arthritis: An analysis of the FRANK Registry. Joint Bone Spine. Published 21 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →